Concert Pharmaceuticals
Concert Home Page - Concert Pharmaceuticals.
Launch date
Employees
Market cap
€365m
Enterprise valuation
€242m (Public information from Mar 2023)
Share price
$8.37 CNCE
Lexington Kentucky (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 131m | 9.1m | <1m | 6.4m | 29.1m | - | 29.1m |
| % growth | - | (93 %) | (90 %) | 600 % | 357 % | - | - |
| EBITDA | 84.5m | (49.1m) | - | (64.5m) | (64.5m) | (111m) | (100m) |
| % EBITDA margin | 65 % | (540 %) | - | (1014 %) | (222 %) | - | (344 %) |
| Profit | 86.4m | (50.9m) | (70.9m) | (67.3m) | (66.4m) | (115m) | (92.7m) |
| % profit margin | 66 % | (560 %) | (7800 %) | (1057 %) | (228 %) | - | (319 %) |
| EV / revenue | 2.7x | 27.6x | 108.0x | 36.4x | - | - | - |
| EV / EBITDA | 4.2x | -5.1x | - | -3.6x | - | -0.4x | - |
| R&D budget | 25.0m | - | 52.0m | - | - | - | - |
| R&D % of revenue | 19 % | - | 5720 % | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $10.0m | Series A | |
$48.5m | Series B | ||
| N/A | $37.0m | Series C | |
$4.0m | Early VC | ||
| N/A | N/A | IPO | |
$30.0m | Post IPO Debt | ||
| N/A | $74.7m | Post IPO Equity | |
$65.0m | Post IPO Equity | ||
* | $66.4m | Post IPO Equity | |
* | $576m Valuation: $576m | Acquisition | |
| Total Funding | €90.5m | ||
Related Content
Recent News about Concert Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.